Cell cycle disruption and apoptotic activity of 3-aminothiazolo[3,2-a]benzimidazole-2-carbonitrile and its homologues

European Journal of Medicinal Chemistry

Volumn 45, Issue 6, 2010, Pages 2689-2694

  Sarhan, Abdelwareth A O ^a   Al Dhfyan, Abdullah ^b   Al Mozaini, Maha A ^b,c   Adra, Chaker N ^b,d   Aboul Fadl, Tarek ^e,f  

^a Assiut University   (Egypt)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e Assiut University   (Egypt)

^f KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

3 Aminothiazolo 3,2 a benzimidazole 2 carbonitrile; Apoptosis; Cell cycle disruption; Cytotoxic activity; G2 M phase

Indexed keywords

3 AMINOTHIAZOLO[3,2 A]BENZIMIDAZOLE 2 CARBNITRILE; 3 AMINOTHIAZOLO[3,2 A]BENZIMIDAZOLE 2 CARBOXAMIDE; BENZIMIDAZOLE DERIVATIVE; ETHYL 3 AMINOTHIAZOLO[3,2 A]BENZIMIDAZOLE 2 CARBOXYLATE; FORMIC ACID; N ACETYLAMINOTHIAZOLO[3,2 A]BENZIMIDAZOLE 2 CARBONITRILE; PHOSPHORIC ACID; PYRIMIDO[4',5':4,5]THIAZOLO[3,2 A]BENZIMIDAZOL 4(3H) ONE; SULFURIC ACID; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYCLIZATION; DRUG HYDROLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; NITRILES;

EID: 77950861035     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.02.025     Document Type: Article

References (38)

1. Lopez-Saez J.F., de la Torre C., Pincheire J., and Gimenez-Martin G. Histol. Histopathol. 13 (1998) 1197-1214
2. Rew D.A., and Wilson G.D. Eur. J. Surg. Oncol. 26 (2000) 405-416
3. Hartwell L.H., and Kastan M.B. Science 266 (1994) 1821-1828
4. Agarwal R. Biochem. Pharmacol. 60 (2000) 1051-1059
5. Weinstein I.B. Carcinogenesis 21 (2000) 857-864
6. Agarwal C., Sharma Y., and Agarwal R. Mol. Carcinogenesis 28 (2000) 129-138
7. Singh R.P., Dhanalakshmi S., and Agarwal R. Cell Cycle 1 (2002) 156-161
8. Lin J.K. Arch. Pharm. Res. 25 (2002) 561-571
9. Sun J., Chu Y.F., Wu X., and Liu R.H. J. Agric. Food Chem. 50 (2002) 7449-7454
10. Katdare M., Osborne M., and Telang N.T. Int. J. Oncol. 21 (2002) 809-815
11. Chinni S.R., Li Y., Upadhyay S., Koppolu P.K., and Sarkar F.H. Oncogene 20 (2001) 2927-2936
12. Park M.J., Kim E.H., Park I.C., Lee H.C., Woo S.H., Lee J.Y., Hong Y.J., Rhee C.H., Choi S.H., Shim B.S., Lee S.H., and Hong S.I. Int. J. Oncol. 21 (2002) 379-383
13. Moragoda L., Jaszewski R., and Majumdar A.P. Anticancer Res. 21 (2001) 873-878
14. Tyagi A.K., Singh R.P., Agarwal C., Chan D.C., and Agarwal R. Clin. Cancer Res. 8 (2002) 3512-3519
15. Lin L., Lin G., Chen W., Guo W., and Lin X. Zhonghua Kouqiang Yixue Zazhi 37 (2002) 94-96
16. Donato J.L., Kutock J.L., Cheng T., Shirakawa T., Mao X.-Q., Beach D., Scadden D.T., Sayegh M.H., and Adra C.N. J. Clin. Invest. 109 (2002) 51-58
17. Chinami M., Yano Y., Yang X., Salahuddin S., Turner H., Shirakawa T., and Adra C.N. J. Biol. Chem. 280 (2005) 17235-17242
18. Dixon H., and Norbury C.J. Cell Cycle 1 (2002) 362-368
19. Kawabe T. Mol. Cancer Ther. 3 (2004) 513-519
20. Lazo J.S., and Tamura K. J. Pharmacol. Exp. Ther. 296 (2001) 364-371
21. Chimirri A., Grasso S., Monforte A.M., Monforte P., and Zappalà M. Il. Farmaco. 46 (1991) 925-933
22. Chimirri A., Monforte P., Musumeci L., Rao A., Zappalà M., and Monforte A.M. Arch. Pharm. 334 (2001) 203-208
23. Chimirri A., Grasso S., Montforte A.M., Montforte P., Zappalà M., and Carotti A. Farmaco 49 (1994) 337-344
24. Mckee T.D., and Suto R.K. PCT Int. Appl. (2002) WO 03 73,999; Chem Abstr 139: 240337x
25. Cozzi P., Mongelli N., and Suarato A. Curr. Med. Chem. - Anticancer Agents 4 (2004) 93-121
26. Grimaudo S., Raimondi M.V., Capone F., Chimirri A., Poretto F., Monforte A.M., Simoni D., and Tolomeo M. Eur. J. Cancer 37 (2001) 122-130
27. Sarhan A.A.O., El-Sherief H.A.H., and Mahmoud A.M. Tetrahedron 52 (1996) 10485-10496
28. Sarhan A.A.O., Hozien Z.A., and El-Sherief H.A.H. Monatsh. Chem. 128 (1997) 1133-1141
29. Sarhan A.A.O., Hozien Z.A., El-Sherief H.A.H., and Mahmoud A.M. Pol. J. Chem. 69 (1995) 1479-1483
30. Sarhan A.A.O., El-Sherief H.A.H., and Mahmoud A.M. J. Chem. Res. (1996) 116-135 (M)
31. Sarhan A.A.O. Afinidad 461 (1996) 57-60 LIII
32. Sarhan A.A.O., El-Sherief H.A.H., and Mahmoud A.M. J. Chem. Res. 1 (1996) 4-5 (S)
33. Greever R., Schepartz S.A., and Chabner B.A. Semin. Oncol. 19 (1992) 622-638
34. Monks A., Scudiero D., Dkehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langely J., Cronise P., Vaigro-Wolf M., Gray-Good Rich M., Campell H., and Mayo M.R. J. Natl. Cancer Inst. 83 (1991) 757-766
35. Fadok V.A., Voelker D.R., Campbell P.A., Cohen J.J., Bratton D.L., and Henson P.M. J. Immunol. 148 (1992) 2207-2216
36. Koopman G., Reutelingsperger C.P.M., Kuijten G.A.M., Keehnen R.M., Pals S.T., and van Oers M.H. Blood 84 (1994) 1415-1420
37. Vermes I., Haanen C., Nakken S.H., and Reutelingsperger C. J. Immunol. Methods 184 (1995) 39-51
38. Del Bino G., Darzynkiewicz Z., Degraef C., Mosselmans R., Fokan D., and Galand P. Cell Prolif. 32 (1999) 25-37